Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Satoshi Saito, Nozomu Muraishi, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada – 16 May 2022 – The aim of this study was to determine the impact at 5 years of sodium‐glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) on liver histopathology and clinical features.

Code of Conduct

The AASLD Communities, Liver Connect forums, (“AASLD Communities” or “Community” or “Liver Connect”) is a service provided by the American Association for the Study of Liver Diseases (referred to as “AASLD,” “we,” “our,” or “us”) for its members. 

Thank you for being part of Liver Connect forums. To ensure the best possible experience for all members, we have established this Code of Conduct governing your participation.

Subscribe to